- During the first quarter of 2017, OWP management has been focused on the following activities to position the company for a commercial relaunch later this year; (1) sourcing and manufacturing additional FDA approved products, (2) pre-marketing to both neurologists and psychiatrists, and (3) tightly controlling spending and raising additional capital to support planned growth.
— OWP Pharmaceuticals Quarterly Update